Blog / Archives
Biotechs Sink Again in Sector Shift to Technology Stocks: Update-1
6/1/17 Update at close...Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a...
Biotech Fades After ASCO Abstract Rally
Biotech Fades with Profit Taking: Is the pre-ASCO Momentum Gone? Technicals Matter Drug Pricing Scrutiny Continues Biotechs faded today now that the rush of oncology drug news slowed down. NASDAQ...
ASCO Abstracts Week: Biotech Trends and Hot Stocks
Biotech Trends: Immuno-Oncology Stocks Trending Strong Await ASCO Meeting on June 2 Prices as of Monday 11:45A with NASDAQ up 0.73% FBT $106.75 up 0.2%, IBB flat at $290.64, XBI at $69.33 up 0.3%...
Biotechs Mired in a Trading Range: Breakout Delayed…Update-3
Update-3...ASCO Movers Today 5/18: IBB up 1.28% to $292.27, XBI up 2% to $70. Nice follow through in biotech after a nasty day on 5/17 attributed to ASCO and a move away from the "Trump Trade"...
Rayno Diagnostics and Tools: Hologic Beats Q1 Sales and EPS
Hologic, Inc. (HOLX) Beats: Revenues Increased 3.2% and GAAP diluted Earnings Increased 666.7% Compared to Prior Year Period (fiscal Q2) The base business grew 5.4% lead by molecular diagnostics,...
Large Cap Biopharmaceutical Valuations: Q1 2017
May 8, 2017 Large Cap Biopharma Valuations After Q1 Earnings Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the...
Rayno Biobeat #3 2017 Biotech Breakout Coming-Update-2
Update: Big Down Day in Biotech XBI down 3% Article to follow: big movers down CELG,KITE, PBYI, TSRO, XLRN etc Update-1... 5/8/17...Biotech Sector Losing Momentum XBI down 4.3% over 5 days although...
Biotechs Running Again: Rayno Life Science Stocks-See Picks…Earnings Updates
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales...
Biotech Sector Leads Market Early in 2017 Despite Uncertainties…Update
Update at Close...April 18 Biopharma takes a step back Healthcare stocks were top loser down 0.93%. Biotechs were hit hard today with many high fliers selling off. Large caps were all down with...
Biotech in a Doldrums: Rallies Interrupted by Geopolitics, Trump Agenda and Flight to Safety
Biotech Doldrums: Nothing to Entice Buyers Trump Agenda for Tax Reform and Deregulation Stalls Geopolitical News Curbs Market Sentiment Recent geopolitical news has created a backdrop that has...